GlassScriptPhysician profile
Vicente Galan
NPI 1831180983
$6,790.08
in general payments reported to CMS, 2019-2025
27 companies · $98.56 in 2025
The $98.56 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,330 · 2020: $602 · 2021: $46.90 · 2022: $1,094 · 2023: $1,189 · 2024: $1,429 · 2025: $98.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807 · Travel and Lodging: $775 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.38 |
| Travel and Lodging | $774.77 |
| Education | $134.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,656.93 | 2019-2024 | Senza |
| Spinal Simplicity, LLC | $964.47 | 2024 | Ha Minuteman G3-R |
| Abbott Laboratories | $797.22 | 2019-2025 | Eterna, Proclaim |
| Medtronic USA, INC. | $747.43 | 2019-2020 | |
| Stimwave Technologies Incorporated | $603.54 | 2019-2022 | |
| Medtronic, INC. | $461.69 | 2023-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Vertiflex, INC. | $347.17 | 2019 | |
| Boston Scientific Corporation | $202.76 | 2019-2023 | Superion Indirect Decompression System |
| Relievant Medsystems, INC. | $172.54 | 2022-2023 | Intracept |
| Spr Therapeutics, INC | $160.09 | 2019-2020 | |
| Curonix LLC | $151.59 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $128.04 | 2023-2024 | Mild Device Kit |
| Foundation Fusion Solutions, LLC | $52.90 | 2024-2025 | |
| Horizon Therapeutics Plc | $47.87 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $39.39 | 2023 | Belbuca |
| Pfizer INC. | $32.83 | 2019-2021 | |
| Daiichi Sankyo INC. | $26.72 | 2019 | |
| Abbvie INC. | $24.22 | 2025 | |
| Valinor Pharma, LLC | $20.72 | 2025 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.92 | 2024 | Relistor |
| Azurity Pharmaceuticals, INC. | $18.61 | 2023 | Horizant |
| Mdd US Operations, LLC | $17.93 | 2019 | |
| Assertio Therapeutics, INC. | $13.81 | 2019 | |
| Amgen INC. | $13.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.13 | 2019 | |
| Bausch Health US, LLC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicente Galan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.